12/3
08:31 am
asnd
Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
Low
Report
Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors
11/29
01:30 am
asnd
Ascendis Pharma (ASND): Is There More Upside in the Valuation After Recent Momentum? [Yahoo! Finance]
Low
Report
Ascendis Pharma (ASND): Is There More Upside in the Valuation After Recent Momentum? [Yahoo! Finance]
11/28
10:23 pm
asnd
How the FDA's TransCon CNP Review Delay at Ascendis Pharma (ASND) Has Changed Its Investment Story [Yahoo! Finance]
Low
Report
How the FDA's TransCon CNP Review Delay at Ascendis Pharma (ASND) Has Changed Its Investment Story [Yahoo! Finance]
11/28
05:52 pm
asnd
How Analyst Views Are Shifting the Ascendis Pharma Story After Recent Yorvipath and Pipeline Updates [Yahoo! Finance]
Low
Report
How Analyst Views Are Shifting the Ascendis Pharma Story After Recent Yorvipath and Pipeline Updates [Yahoo! Finance]
11/26
09:17 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/25
07:09 pm
asnd
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia [Yahoo! Finance]
Medium
Report
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia [Yahoo! Finance]
11/25
06:15 pm
asnd
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
Low
Report
Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia
11/20
06:01 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/18
09:02 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $220.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $220.00 price target on the stock.
11/18
09:00 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Wolfe Research. They set a "peer perform" rating and a $255.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Wolfe Research. They set a "peer perform" rating and a $255.00 price target on the stock.
11/17
04:01 pm
asnd
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
Low
Report
Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics
11/13
12:41 pm
asnd
Ascendis (ASND) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Ascendis (ASND) Q3 2025 Earnings Call Transcript [Yahoo! Finance]
11/12
09:08 pm
asnd
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Ascendis Pharma A/S (ASND) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/12
04:01 pm
asnd
Ascendis Pharma Reports Third Quarter 2025 Financial Results
Medium
Report
Ascendis Pharma Reports Third Quarter 2025 Financial Results
11/8
10:43 pm
asnd
The Bull Case For Ascendis Pharma (ASND) Could Change Following New Long-Term Renal Data on TransCon PTH [Yahoo! Finance]
Low
Report
The Bull Case For Ascendis Pharma (ASND) Could Change Following New Long-Term Renal Data on TransCon PTH [Yahoo! Finance]
11/7
08:30 am
asnd
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism
Low
Report
New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism
11/5
04:01 pm
asnd
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025
Low
Report
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025
11/3
04:01 pm
asnd
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
Medium
Report
3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025
10/18
07:31 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.
10/17
08:46 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating and a $271.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Raymond James Financial, Inc.. They set a "strong-buy" rating and a $271.00 price target on the stock.
10/16
10:39 am
asnd
Ascendis Pharma (NasdaqGS:ASND): Evaluating Valuation After Sharply Higher Share Price This Quarter [Yahoo! Finance]
Low
Report
Ascendis Pharma (NasdaqGS:ASND): Evaluating Valuation After Sharply Higher Share Price This Quarter [Yahoo! Finance]
10/13
08:44 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) was given a new $254.00 price target on by analysts at Cantor Fitzgerald.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) was given a new $254.00 price target on by analysts at Cantor Fitzgerald.
10/9
08:58 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $260.00 to $264.00. They now have an "overweight" rating on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at JPMorgan Chase & Co. from $260.00 to $264.00. They now have an "overweight" rating on the stock.
10/8
04:19 pm
asnd
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia [Yahoo! Finance]
Medium
Report
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia [Yahoo! Finance]
10/8
04:01 pm
asnd
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia
Low
Report
Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia